MAPT and early-onset autosomal dominant Alzheimer disease: Regular oral administration of SFN at a daily dose of 10 to 50 mg/kg prevented memory impairment characteristic of Alzheimer’s disease and reduced levels of tau, phosphorylated tau, and Aβ-protein—key pathophysiological factors in this disease.